EGFR tyrosine kinase inhibition (EGFR-TKI) has been included in the guidelines as a first-line treatment option for patients with EGFR driver-positive advanced lung cancer, and the clinical efficacy of ositinib, a 3rd-generation EGFR-TKI targeted drug that acts on T790M-positive mutations, has been confirmed in a wide range of clinical trials. The gene discussed is EGFR; the disease is lung cancer.